 Cannabinoid Receptor Agonists
"Cannabinoid Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS.
| Descriptor ID |
D063386
|
| MeSH Number(s) |
D27.505.519.625.085.500 D27.505.696.399.472.188.500
|
| Concept/Terms |
Cannabinoid Receptor Agonists- Cannabinoid Receptor Agonists
- Agonists, Cannabinoid Receptor
- Receptor Agonists, Cannabinoid
- Cannabinoid Receptor Activators
- Activators, Cannabinoid Receptor
- Receptor Activators, Cannabinoid
- Cannabinoid Agonists
- Agonists, Cannabinoid
|
Below are MeSH descriptors whose meaning is more general than "Cannabinoid Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Cannabinoid Receptor Agonists".
This graph shows the total number of publications written about "Cannabinoid Receptor Agonists" by people in UAMS Profiles by year, and whether "Cannabinoid Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 0 | 1 | | 2023 | 0 | 2 | 2 | | 2022 | 0 | 9 | 9 | | 2020 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2018 | 2 | 0 | 2 | | 2017 | 2 | 0 | 2 | | 2016 | 0 | 2 | 2 | | 2015 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2012 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cannabinoid Receptor Agonists" by people in Profiles over the past ten years.
-
Jones AT, Marwan Abu Taha A, Miller GP. The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications. Neurosci Biobehav Rev. 2025 Mar; 170:106043.
-
Borodovsky JT, Struble CA, Habib MI, Hasin DS, Shmulewitz D, Walsh C, Livne O, Aharonovich E, Budney AJ. Exploring survey methods for measuring consumption quantities of cannabis flower and concentrate products. Am J Drug Alcohol Abuse. 2023 11 02; 49(6):733-745.
-
al'Absi M, DeAngelis BN, Nakajima M, Hodges JS, Budney A, Hatsukami D, Allen S. Biobehavioral and affective stress responses during nicotine withdrawal: Influence of regular cannabis co-use. Psychopharmacology (Berl). 2024 Feb; 241(2):253-262.
-
Borodovsky JT, Hasin DS, Shmulewitz D, Walsh C, Livne O, Aharonovich E, Struble CA, Habib MI, Budney AJ. Typical Hits, Grams, or Joints: Evaluating Cannabis Survey Measurement Strategies for Quantifying Consumption. Cannabis Cannabinoid Res. 2024 Apr; 9(2):646-658.
-
Budney AJ, Borodovsky JT, Struble CA, Habib MI, Shmulewitz D, Livne O, Aharonovich E, Walsh C, Cuttler C, Hasin DS. Estimating THC Consumption from Smoked and Vaped Cannabis Products in an Online Survey of Adults Who Use Cannabis. Cannabis Cannabinoid Res. 2024 Apr; 9(2):688-698.
-
Wilson CD, Zheng F, Fantegrossi WE. Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice. Psychopharmacology (Berl). 2022 Oct; 239(10):3237-3248.
-
Kearney-Ramos T, Herrmann ES, Belluomo I, Matias I, Vall?e M, Monlezun S, Piazza PV, Haney M. The Relationship Between Circulating Endogenous Cannabinoids and the Effects of Smoked Cannabis. Cannabis Cannabinoid Res. 2023 12; 8(6):1069-1078.
-
Cabanlong CV, Russell LN, Fantegrossi WE, Prather PL. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicol Sci. 2022 04 26; 187(1):175-185.
-
Wilson CD, Hiranita T, Fantegrossi WE. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. Drug Alcohol Depend. 2022 07 01; 236:109468.
-
Forsyth AD, Kulik MC, Richmond McKnight T, Perkins AD, Balla A. University of California Cannabis Research Workshop, May 2021: Meeting Summary. Cannabis Cannabinoid Res. 2022 04; 7(2):152-155.
-
al'Absi M, DeAngelis B, Fiecas M, Budney A, Allen S. Effects of regular cannabis and nicotine use on acute stress responses: chronic nicotine, but not cannabis use, is associated with blunted adrenocortical and cardiovascular responses to stress. Psychopharmacology (Berl). 2022 May; 239(5):1551-1561.
-
Kelleghan AR, Sofis MJ, Budney A, Ceasar R, Leventhal AM. Associations of cannabis product source and subsequent cannabis use among adolescents. Drug Alcohol Depend. 2022 04 01; 233:109374.
-
Connor JP, Stjepanovic D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction. 2022 07; 117(7):2075-2095.
-
Oppong-Damoah A, Gannon BM, Murnane KS. The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism? CNS Neurol Disord Drug Targets. 2022; 21(1):3-13.
-
Yang JF, Williams AH, Penthala NR, Prather PL, Crooks PA, Zhan CG. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. ACS Chem Neurosci. 2020 10 21; 11(20):3455-3463.
-
Samanta D. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatr Neurol. 2019 07; 96:24-29.
-
Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug Alcohol Depend. 2018 11 01; 192:285-293.
-
Schlienz NJ, Lee DC, Stitzer ML, Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018 06 01; 187:254-260.
-
Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov; 125(Pt B):161-177.
-
Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci. 2017; 32:249-262.
-
Ford BM, Franks LN, Radominska-Pandya A, Prather PL. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. PLoS One. 2016; 11(12):e0167240.
-
Pinheiro BS, Lemos C, Neutzling Kaufmann F, Marques JM, da Silva-Santos CS, Carvalho E, Mackie K, Rodrigues RJ, Cunha RA, K?falvi A. Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin. Brain Res Bull. 2016 06; 124:222-30.
-
Jalin AM, Rajasekaran M, Prather PL, Kwon JS, Gajulapati V, Choi Y, Kim C, Pahk K, Ju C, Kim WK. Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. PLoS One. 2015; 10(10):e0141600.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|